Cargando…
Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844610/ https://www.ncbi.nlm.nih.gov/pubmed/35199091 http://dx.doi.org/10.1016/j.xjidi.2021.100092 |
_version_ | 1784651514677035008 |
---|---|
author | Sakai, Takashi Herrmann, Nadine Maintz, Laura Nümm, Tim Joachim Welchowski, Thomas Claus, Ralf A. Gräler, Markus H. Bieber, Thomas |
author_facet | Sakai, Takashi Herrmann, Nadine Maintz, Laura Nümm, Tim Joachim Welchowski, Thomas Claus, Ralf A. Gräler, Markus H. Bieber, Thomas |
author_sort | Sakai, Takashi |
collection | PubMed |
description | Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is known about the circulating lipids in patients with AD. In this study, we explored the changes of serum phospholipids in AD using liquid chromatography coupled to tandem mass spectrometry and sought serum lipids’ contribution to clinical status. Several serum levels of phospholipids were altered in the AD group (n = 179) compared with that in healthy controls (n = 47) and patients without AD with atopic comorbidities (n = 22); lipids exhibiting the apparent changes included increased sphingosine, multiple variants of phosphatidylcholine, and decreased ceramide (16:0) in patients with AD. Moreover, serum levels of sphingosine correlated with the severity of AD, and sphingosine and ceramide(16:0) were also detected as the risk-increasing effect and risk-reduction effect of AD, respectively. In summary, alterations in the serum concentration of phospholipids are seen in patients with AD. Although more detailed investigations will be needed to evaluate the significance of the changes in circulating lipids in AD, these findings can provide, to our knowledge, previously unreported insight into AD’s pathogenesis and therapeutic strategies. |
format | Online Article Text |
id | pubmed-8844610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88446102022-02-22 Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status Sakai, Takashi Herrmann, Nadine Maintz, Laura Nümm, Tim Joachim Welchowski, Thomas Claus, Ralf A. Gräler, Markus H. Bieber, Thomas JID Innov Original Article Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is known about the circulating lipids in patients with AD. In this study, we explored the changes of serum phospholipids in AD using liquid chromatography coupled to tandem mass spectrometry and sought serum lipids’ contribution to clinical status. Several serum levels of phospholipids were altered in the AD group (n = 179) compared with that in healthy controls (n = 47) and patients without AD with atopic comorbidities (n = 22); lipids exhibiting the apparent changes included increased sphingosine, multiple variants of phosphatidylcholine, and decreased ceramide (16:0) in patients with AD. Moreover, serum levels of sphingosine correlated with the severity of AD, and sphingosine and ceramide(16:0) were also detected as the risk-increasing effect and risk-reduction effect of AD, respectively. In summary, alterations in the serum concentration of phospholipids are seen in patients with AD. Although more detailed investigations will be needed to evaluate the significance of the changes in circulating lipids in AD, these findings can provide, to our knowledge, previously unreported insight into AD’s pathogenesis and therapeutic strategies. Elsevier 2021-12-22 /pmc/articles/PMC8844610/ /pubmed/35199091 http://dx.doi.org/10.1016/j.xjidi.2021.100092 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Sakai, Takashi Herrmann, Nadine Maintz, Laura Nümm, Tim Joachim Welchowski, Thomas Claus, Ralf A. Gräler, Markus H. Bieber, Thomas Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title | Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title_full | Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title_fullStr | Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title_full_unstemmed | Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title_short | Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status |
title_sort | altered serum phospholipids in atopic dermatitis and association with clinical status |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844610/ https://www.ncbi.nlm.nih.gov/pubmed/35199091 http://dx.doi.org/10.1016/j.xjidi.2021.100092 |
work_keys_str_mv | AT sakaitakashi alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT herrmannnadine alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT maintzlaura alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT nummtimjoachim alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT welchowskithomas alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT clausralfa alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT gralermarkush alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus AT bieberthomas alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus |